The decision means the therapy is available for restricted use in the NHS in Scotland.
Tredaptive contains extended release nicotinic acid 1g and the anti-flushing treatment laropiprant 20mg. GPs can prescribe the drug to treat dyslipidaemia, mixed dyslipidaemia and hypercholesterolaemia in patients for whom statins are not tolerated.
This is the first nicotinic acid formulation accepted by the SMC. In trials, the drug cut LDL cholesterol by 18 per cent and triglycerides by 26 per cent, while raising HDL cholesterol by 20 per cent (placebo adjusted).